Epicardial VT ablation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia after failed endocardial ablation resulted in no VT in 77% of patients over 18±13 months.
Observational (n=13)
Background— Efficacy of endocardial ventricular tachycardia (VT) ablation in arrhythmogenic right ventricular cardiomyopathy/dysplasia may be limited by epicardial VT, right ventricular thickening, or both. We sought to characterize the endocardial versus epicardial substrate, measure right ventricular free wall thickness, and determine epicardial ablation efficacy in patients with right ventricular cardiomyopathy/dysplasia. Methods and Results— Thirteen consecutive patients (3 female; aged 43±15 years; range, 17 to 70 years) undergoing endocardial and epicardial sinus rhythm voltage mapping and epicardial VT ablation after failed endocardial VT ablation were included. In each patient, the low bipolar voltage area (10 mm in 6 of 13 patients compared with 5 to 10 mm in 4 reference patients without structural disease. Twenty-seven VTs were targeted on the epicardium with the use of activation, entrainment, or pace mapping with focal/linear ablation and targeting of late potentials. Epicardial VTs were targeted opposite normal endocardium in 10 patients (77%) and/or opposite ineffective endocardial ablation sites in 11 patients (85%). During 18±13 months, 10 of the 13 patients (77%) had no VT, with 2 patients having only a single VT at 2 and 38 months, respectively. Conclusions— Patients with right ventricular cardiomyopathy/dysplasia and VT after endocardial ablation have a more extensive epicardial area of electrogram abnormalities and frequently have basal right ventricular wall thickening. Epicardial substrate and VT mapping identifies targets, and ablation results in VT control.
García et al. (Mon,) conducted a observational in Arrhythmogenic right ventricular cardiomyopathy/dysplasia with ventricular tachycardia (n=13). Epicardial VT ablation was evaluated on Freedom from VT. Epicardial VT ablation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia after failed endocardial ablation resulted in no VT in 77% of patients over 18±13 months.